Compare ECO & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ECO | SUPN |
|---|---|---|
| Founded | 2018 | 2005 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.5B |
| IPO Year | 2023 | 2010 |
| Metric | ECO | SUPN |
|---|---|---|
| Price | $90.09 | $41.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $69.67 | $60.50 |
| AVG Volume (30 Days) | ★ 734.1K | 723.4K |
| Earning Date | 11-11-2026 | 10-29-2026 |
| Dividend Yield | ★ 10.47% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $392,755,000.00 |
| Revenue This Year | $116.49 | $22.95 |
| Revenue Next Year | N/A | $54.39 |
| P/E Ratio | $18.60 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $31.75 | $37.54 |
| 52 Week High | $100.68 | $59.68 |
| Indicator | ECO | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 57.10 | 47.61 |
| Support Level | $47.47 | $40.51 |
| Resistance Level | $100.68 | $52.30 |
| Average True Range (ATR) | 4.32 | 1.72 |
| MACD | -0.93 | -0.00 |
| Stochastic Oscillator | 29.31 | 67.43 |
Okeanis Eco Tankers Corp is an international owner and operator of a fleet of tanker vessels used for the transportation of crude oil. Its fleet consists of modern Suezmax and VLCC tankers that are designed in accordance with eco-efficiency standards, including features such as reduced fuel consumption, exhaust gas cleaning systems, and ballast water treatment systems. All of the company's revenue is derived from a single segment, the crude oil tanker segment. Geographically, the maximum revenue is generated from Europe, and the rest from Asia, North America, and South America.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.